Caliway Reports Positive Phase 2 Results for CBL-514 in Dercum
New Taipei City, Taiwan, September 22, 2026 Caliway Biopharmaceuticals has announced positive final results from its randomized, single-blind, placebo-controlled...
Phase 2 clinical trial
Advertisement
Abbisko Therapeutics Reports Positive Phase 2 Lavengratinib Data
Shanghai, China, September 21, 2026 Abbisko Therapeutics has announced positive preliminary results from a Phase 2 clinical study evaluating...
Bright Path Labs Receives FDA AMT Designation for Medicines
Mesa, Arizona, U.S., September 14, 2026 Bright Path Labs, a U.S.-based pharmaceutical manufacturer, announced that the U.S. Food and...
Armata’s AP-SA02 Receives FDA Breakthrough Designation
Los Angeles, California, U.S., September 14, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has...
Tyra Reports Phase 2 Dabogratinib Results in Bladder Cancer
San Diego, California, September 10, 2026 Tyra Biosciences, Inc. has reported initial results from the Phase 2 SURF302 clinical...
Advertisements
Kenvue’s TYLENOL With Naproxen Shows Lasting Pain Relief
Fort Washington, Pennsylvania, U.S., September 8, 2026 New clinical evidence presented at PAINWeek 2026 highlights the potential of a...
INBRX-106 Doubles Response Rate in Phase 2 HNSCC
San Diego, California, U.S., September 8, 2026 Inhibrx Biosciences, Inc. has reported positive primary endpoint results from the randomized...
BMS Reports Positive Phase 2 CAR T Cell Trial Results
Princeton, New Jersey, U.S., September 8, 2026 Bristol Myers Squibb (BMS) has announced positive topline results from the registrational...
Tyra to Present Dabogratinib Phase 2 Bladder Cancer Data
Carlsbad, California, USA, September 4, 2026 Tyra Biosciences, Inc. has announced that it will host a conference call and...
Inhibrx to Present INBRX-106 Phase 2 HNSCC Results
San Diego, California, USA, September 4, 2026 Inhibrx Biosciences, Inc. has announced plans to host a live webcast presentation...
Advertisement
